絞り込み

16639

広告

Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.

著者 Ageno W , Lopes RD , Yee MK , Hernandez A , Hull R , Goldhaber SZ , Gibson CM , Cohen AT
J Thromb Haemost.2019 Aug 08 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (26view , 0users)

Full Text Sources

Miscellaneous

Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk-benefit of betrixaban in patients aged ≥80 years enrolled in the APEX trial.
PMID: 31392827 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード